In November 2016 our lives took a sudden and heartbreaking turn when our three-year-old daughter, Bianca, was diagnosed with a very rare and aggressive form of brain cancer called ETMR. We will never forget that dark Tuesday afternoon at London’s Great Ormond Street Hospital when we were given the results of her histology. We knew something was wrong when we saw Bianca’s neurosurgeon waiting for us with an entourage that included a neuro-oncologist and a social worker: “We were surprised. It’s much worse than we expected,” the oncologist said. “Bianca has an extremely rare grade IV brain cancer called ETMR.” But the worst was yet to come; he later told us that our options were either to go home and “make her comfortable,” or radiate her whole brain and spine with devastating consequences and a dismal prognosis. When we arrived back home that afternoon Bianca was playing with her twin sister, full of life and healthy in appearance. That day we did not have the strength to look her in the eyes. We were devastated beyond words.


Unsatisfied with the limited treatment options we were offered in London, we decided to leave the UK. After a week of intensive research we made the decision to relocate to Boston where Bianca has been treated ever since. Her difficult journey is still ongoing. Bianca’s strength and positivity, as well as the countless wonderful doctors, nurses, researchers and other families we have met along the way, have been deeply humbling and inspiring.


Over the past year we have gotten to know the world of pediatric oncology well and its sad realities, the most appalling of which being the inexplicable lack of research funding. Most pediatric cancers are extremely rare; as a result they do not ‘financially justify’ any investment in research. These diseases are thus largely ignored by the pharmaceutical industry and receive only 4% of government oncology research grants. In the past 20 years only three drugs have been approved that were specifically developed to treat children with cancer. The lack of a protocol for many of these cancers makes the difficult journey for families even lonelier. This is unacceptable and we cannot let these children down.


Naturally we have decided to dedicate a large part of our lives to supporting research for the rarest pediatric cancers: those which need funding the most. To that purpose we have decided to create ‘The Bibi Fund’ in partnership with a wonderful and inspiring organization, Solving Kids’ Cancer (SKC). The goal of ‘The Bibi Fund’ is simple: Funding research with a focus on the rarest childhood cancers.


In order to make ‘The Bibi Fund’ a success and ultimately save children’s lives we need all the support we can get. We thank you from the bottom our hearts for reading our story and we hope you will join us in supporting this very important cause. 


With love,

The Niedzielski Family (Bianca, Stella, Gisela and Michael)

About Solving Kids' Cancer (SKC)

  • 100% of all donations go to research.
  • SKC is an independent and nonprofit organization which invests in the highest-impact research projects without any ties to any particular research institution or hospital.
  • SKC works across borders and in collaboration with other like-minded nonprofit organizations.
  • SKC has a world-renowned scientific board and a proven track record in finding, funding and advocating for innovative research projects, which create more novel and less toxic treatment options for children with cancer and ultimately save lives.
  • SKC is a certified 501(c)(3) organization based in New York City.  Donations are tax deductible (EIN: 20-8735688)


Donations are tax deductible to the fullest extent allowed by law.  No goods or services are received in exchange for donations made to Solving Kids' Cancer via The Bibi Fund.  If you are an overseas donor, talk to your tax advisor about your potential tax benefit.